CO6592112A2 - Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciòn - Google Patents
Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciònInfo
- Publication number
- CO6592112A2 CO6592112A2 CO12141229A CO12141229A CO6592112A2 CO 6592112 A2 CO6592112 A2 CO 6592112A2 CO 12141229 A CO12141229 A CO 12141229A CO 12141229 A CO12141229 A CO 12141229A CO 6592112 A2 CO6592112 A2 CO 6592112A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- separation
- pyridine derivatives
- medicines containing
- tricyclic pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos definidos por la fórmula (I) en la que las variables se R-Rdefinen como en la descripción, poseen actividad farmacológica valiosa. Particularmente, los compuestos son inhibidores de la proteína de transferencia de éster de colesterol (CETP) y, por lo tanto, son adecuados para el tratamiento y prevención de enfermedades que pueden influenciarse por la inhibición de esta enzima.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10154086 | 2010-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6592112A2 true CO6592112A2 (es) | 2013-01-02 |
Family
ID=43877277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12141229A CO6592112A2 (es) | 2010-02-19 | 2012-08-21 | Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciòn |
Country Status (22)
Country | Link |
---|---|
US (2) | US20120053197A1 (es) |
EP (1) | EP2536733B1 (es) |
JP (1) | JP5780528B2 (es) |
KR (1) | KR20130000379A (es) |
CN (1) | CN102869667A (es) |
AP (1) | AP2012006390A0 (es) |
AR (1) | AR080228A1 (es) |
AU (1) | AU2011217206A1 (es) |
BR (1) | BR112012020591A2 (es) |
CA (1) | CA2790643A1 (es) |
CL (1) | CL2012002035A1 (es) |
CO (1) | CO6592112A2 (es) |
EA (1) | EA201201160A1 (es) |
EC (1) | ECSP12012157A (es) |
MA (1) | MA34007B1 (es) |
MX (1) | MX2012009149A (es) |
PE (1) | PE20121743A1 (es) |
SG (1) | SG183321A1 (es) |
TN (1) | TN2012000418A1 (es) |
TW (1) | TW201139445A (es) |
UY (1) | UY33229A (es) |
WO (1) | WO2011101424A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2268644T3 (pl) * | 2008-03-05 | 2012-01-31 | Boehringer Ingelheim Int | Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania |
US20120053197A1 (en) | 2010-02-19 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130053404A1 (en) * | 2011-02-17 | 2013-02-28 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US9150583B2 (en) | 2011-08-17 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130210851A1 (en) * | 2011-08-18 | 2013-08-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative |
US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
CN103882766B (zh) * | 2014-03-21 | 2015-10-28 | 湖南中烟工业有限责任公司 | 一种除去包装卡纸中酮类物质的除酮添加剂及其应用 |
CN103866646B (zh) * | 2014-03-21 | 2015-10-28 | 湖南中烟工业有限责任公司 | 一种生产无酮转移卡纸的工艺 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4798619A (en) | 1980-06-02 | 1989-01-17 | American Cyanamid Co. | 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents |
US4475407A (en) | 1982-12-27 | 1984-10-09 | Brunswick Corporation | Temperature compensated flow sensor |
CH664578A5 (de) * | 1985-01-15 | 1988-03-15 | Ciba Geigy Ag | Ringsubstituierte 4-azaphthalide. |
JPH04500506A (ja) | 1988-08-16 | 1992-01-30 | ジ・アップジョン・カンパニー | Acat酵素をブロックするのに有効な二価リガンド類 |
AP876A (en) | 1995-09-29 | 2000-09-27 | Glaxo Wellcome Spa | Tetrahydroquinolines as NMDA antagonists. |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
HUP0004935A3 (en) | 1997-09-04 | 2001-12-28 | Basf Ag | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
JP3955180B2 (ja) | 1998-09-25 | 2007-08-08 | ファルマシア・コーポレーション | コレステリルエステル伝達タンパク質活性を阻害するのに有用な(R)−キラルなハロゲン化された1−置換アミノ−(n+1)−アルカノール |
US20010018446A1 (en) | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US6479552B2 (en) | 1999-09-23 | 2002-11-12 | G.D. Searle & Co. | Use of substituted N, N-disubstituted diamino compounds for inhibiting cholesteryl ester transfer protein activity |
US6683113B2 (en) | 1999-09-23 | 2004-01-27 | Pharmacia Corporation | (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
DE10238243A1 (de) * | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
AU2005233160B2 (en) | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
PE20060653A1 (es) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
DE102004060997A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Chemische Verbindung und ihre Verwendung |
AU2005315770B2 (en) | 2004-12-18 | 2011-12-08 | Bayer Schering Pharma Aktiengesellschaft | 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments |
BRPI0519566A2 (pt) | 2004-12-18 | 2009-01-27 | Bayer Healthcare Ag | derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp |
JP2008201760A (ja) * | 2007-02-22 | 2008-09-04 | Tokyo Univ Of Agriculture & Technology | 光学活性スピロ化合物及びその製造方法 |
PL2268644T3 (pl) * | 2008-03-05 | 2012-01-31 | Boehringer Ingelheim Int | Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania |
TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
US20120053197A1 (en) | 2010-02-19 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130053404A1 (en) | 2011-02-17 | 2013-02-28 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US9150583B2 (en) | 2011-08-17 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130210851A1 (en) | 2011-08-18 | 2013-08-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative |
-
2011
- 2011-02-17 US US13/029,690 patent/US20120053197A1/en not_active Abandoned
- 2011-02-17 WO PCT/EP2011/052376 patent/WO2011101424A1/en active Application Filing
- 2011-02-17 CA CA 2790643 patent/CA2790643A1/en not_active Abandoned
- 2011-02-17 BR BR112012020591A patent/BR112012020591A2/pt not_active IP Right Cessation
- 2011-02-17 JP JP2012553323A patent/JP5780528B2/ja active Active
- 2011-02-17 MA MA35152A patent/MA34007B1/fr unknown
- 2011-02-17 KR KR20127021473A patent/KR20130000379A/ko not_active Application Discontinuation
- 2011-02-17 PE PE2012001247A patent/PE20121743A1/es not_active Application Discontinuation
- 2011-02-17 CN CN2011800198873A patent/CN102869667A/zh active Pending
- 2011-02-17 MX MX2012009149A patent/MX2012009149A/es not_active Application Discontinuation
- 2011-02-17 EP EP20110704227 patent/EP2536733B1/en active Active
- 2011-02-17 AP AP2012006390A patent/AP2012006390A0/xx unknown
- 2011-02-17 EA EA201201160A patent/EA201201160A1/ru unknown
- 2011-02-17 US US13/029,697 patent/US9029544B2/en active Active
- 2011-02-17 UY UY33229A patent/UY33229A/es not_active Application Discontinuation
- 2011-02-17 SG SG2012060273A patent/SG183321A1/en unknown
- 2011-02-17 AU AU2011217206A patent/AU2011217206A1/en not_active Abandoned
- 2011-02-18 AR ARP110100517 patent/AR080228A1/es unknown
- 2011-02-18 TW TW100105535A patent/TW201139445A/zh unknown
-
2012
- 2012-07-20 CL CL2012002035A patent/CL2012002035A1/es unknown
- 2012-08-16 TN TNP2012000418A patent/TN2012000418A1/en unknown
- 2012-08-21 CO CO12141229A patent/CO6592112A2/es unknown
- 2012-09-14 EC ECSP12012157 patent/ECSP12012157A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2536733B1 (en) | 2014-11-26 |
AP2012006390A0 (en) | 2012-08-31 |
US20120053197A1 (en) | 2012-03-01 |
KR20130000379A (ko) | 2013-01-02 |
AU2011217206A1 (en) | 2012-08-02 |
CA2790643A1 (en) | 2011-08-25 |
SG183321A1 (en) | 2012-09-27 |
EA201201160A1 (ru) | 2013-04-30 |
TN2012000418A1 (en) | 2014-01-30 |
EP2536733A1 (en) | 2012-12-26 |
CL2012002035A1 (es) | 2013-02-01 |
CN102869667A (zh) | 2013-01-09 |
JP2013519709A (ja) | 2013-05-30 |
AR080228A1 (es) | 2012-03-21 |
US20120046304A1 (en) | 2012-02-23 |
JP5780528B2 (ja) | 2015-09-16 |
US9029544B2 (en) | 2015-05-12 |
WO2011101424A1 (en) | 2011-08-25 |
MA34007B1 (fr) | 2013-02-01 |
ECSP12012157A (es) | 2012-10-30 |
PE20121743A1 (es) | 2012-12-22 |
UY33229A (es) | 2011-09-30 |
TW201139445A (en) | 2011-11-16 |
MX2012009149A (es) | 2012-09-28 |
BR112012020591A2 (pt) | 2017-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6592112A2 (es) | Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciòn | |
ECSP12012230A (es) | Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores | |
ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
CR20130371A (es) | IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
BR112012012617B8 (pt) | processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato | |
BR112013000275A2 (pt) | derivados de tetraidro-pirido-pirimidina | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
ECSP15006871A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
ECSP15045801A (es) | Inhibidores de la phd de 6(5hidroxi1hpirazol1il)nicotinamida | |
CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
UY39338A (es) | Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos | |
UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
BR112015005168A2 (pt) | Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos | |
ECSP12011909A (es) | Derivados de glicósido y usos de los mismos | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
BR112013019354A2 (pt) | derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inibidores de fosfodiesterases | |
BR112012023752A2 (pt) | derivados de pirrolopirazina e seu uso como inibidores de jak e syk | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
IN2014DN08551A (es) | ||
BR112018004347A2 (pt) | derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida |